About
Standards

By Category

RecoveryLongevityCognitiveMetabolicAestheticsImmuneGrowth hormoneHormonal

Popular

BPC-157NAD+GLP-2 (T)SemaxGHK-CuThymosin Alpha 1

Stacks

GLOW (skin)KLOW (immune)BPC/TB500 (recovery)CJC/Ipamorelin (GH)

Shop

All peptidesProduct certificatesSubscribe & save

Help

FAQContact us

Policies

ShippingReturns & refundsTerms & conditionsPrivacy policy
Affiliates
Earn 15% on every referral
Share OSYRIS, earn commission. Your audience gets 10% off.
Learn more →
AboutStandards
Home/Shop/Metabolic & Weight Management/Cagrilinitide
Cagrilinitide research peptide vial — OSYRIS Health
METABOLIC

Cagrilinitide

$99.99

Cagrilinitide is a synthetic, long-acting peptide analogue of amylin developed for research applications. It incorporates targeted amino acid substitutions and fatty acid acylation to enhance molecular stability and receptor interaction duration. This compound is supplied exclusively for laboratory research and experimental investigation.

Quantity10mg
PurityPending COA
Free shipping on orders over $200
Download Certificate of Analysis
Research On This Compound

Cagrilinitide — The amylin approach

8 min read · 4 citations · Amylin, appetite, metabolic signaling

COMPARISON

Cagrilinitide vs GLP-1

Amylin vs incretin

CATEGORY GUIDE

Metabolic peptides

Incretins, fat metabolism, exercise mimetics

COMPARISON

GLP-1 vs GLP-2 vs GLP-3

The incretin agonist progression

ROUNDUP

Best metabolic peptides

Weight and metabolism research shortlist

Practical Guides

How to read a certificate of analysis

Peptide storage and handling

Understanding peptide purity testing

About This Compound

Product Overview

Cagrilinitide is a long-acting amylin receptor agonist. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells after meals, and it plays a role in appetite regulation, gastric emptying, and postprandial glucose control. Cagrilinitide was developed as a modified analog of amylin with improved pharmacokinetic properties for research applications.

The compound represents a different pharmacological approach to metabolic research compared to the GLP-1 agonists in the OSYRIS catalog. While GLP-1 agonists work through incretin receptor signaling, cagrilinitide works through the amylin receptor system — a distinct but complementary pathway in metabolic regulation. Research has investigated cagrilinitide both as a standalone compound and in combination with GLP-1 agonists to study whether dual-pathway targeting produces enhanced metabolic effects.

Cagrilinitide amylin receptor signaling research visualization — OSYRIS Health
Research Applications

Mechanism and Experimental Context

Cagrilinitide acts on amylin receptors (AMY1, AMY2, AMY3) — receptor complexes formed by the calcitonin receptor combined with receptor activity-modifying proteins (RAMPs). Amylin receptor activation in the brain's area postrema and nucleus of the solitary tract is associated with reduced food intake and delayed gastric emptying in animal models.1

Research interest in amylin agonists was originally driven by the success of pramlintide (Symlin), an FDA-approved amylin analog for use in diabetes management. Cagrilinitide represents the next generation of amylin analogs with modifications designed to extend duration of action for research purposes.

In preclinical models, cagrilinitide treatment reduced food intake and body weight through central appetite suppression pathways that are distinct from GLP-1 receptor-mediated satiety. The amylin system appears to modulate meal size and meal frequency through brainstem circuits rather than the hypothalamic circuits primarily targeted by leptin signaling.2

A significant area of cagrilinitide research involves its combination with GLP-1 agonists. The CagriSema program studied the combination of cagrilinitide and semaglutide, investigating whether amylin + GLP-1 dual agonism produces effects beyond either pathway alone. Preclinical and clinical data have shown that the combination produced greater metabolic effects than either compound individually.3

Explore Related Compounds

Keep the Research Trail Moving

GLP – 1 (S) research peptide vial — OSYRIS Health

GLP – 1 (S)

GLP-1 agonist for comparison research

$64.99
View →
GLP – 2 (T) research peptide vial — OSYRIS Health

GLP – 2 (T)

dual agonist metabolic research

$99.99 - $169.99
View →
AOD-9604 research peptide vial — OSYRIS Health

AOD-9604

fat metabolism research

$49.99
View →
Referenced Studies

Source Literature

[1]

Lutz TA. "Control of energy homeostasis by amylin." Cellular and Molecular Life Sciences, 2012. PubMed: PMID 21960068

[2]

Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide." Diabetes Care, 2021. PubMed: PMID 33637562

[3]

Frias JP, et al. "Efficacy and safety of co-administered once-weekly cagrilintide plus once-weekly semaglutide." Lancet, 2023.

Certificate of Analysis

Batch Documentation

Current published batch documentation is surfaced on-page whenever the provider exposes a public COA asset.

Certificate Pending

A public COA asset is not currently available for this product. This page will surface the batch document as soon as it is published.

Frequently Asked Questions

Questions About Cagrilinitide

Cagrilinitide is a long-acting amylin receptor agonist studied in appetite regulation and metabolic research. It works through the amylin system — a distinct pathway from the GLP-1 agonists.

Amylin is a peptide hormone released from pancreatic beta cells alongside insulin after meals. It plays a role in appetite regulation, gastric emptying, and blood sugar control.

They target different receptor systems. GLP-1 agonists work through incretin receptors. Cagrilinitide works through amylin receptors. These pathways regulate appetite through different brain circuits. Researchers study them both individually and in combination.

CagriSema is the research program name for the combination of cagrilinitide + semaglutide (a GLP-1 agonist). Studies investigated whether targeting both amylin and GLP-1 pathways simultaneously produces enhanced metabolic effects.

No. Cagrilinitide is a research compound. The CagriSema combination has been in clinical development by Novo Nordisk, but OSYRIS Cagrilinitide is sold exclusively for laboratory research.

Store lyophilized at -20°C for long-term or 2-8°C for short-term. Protect from light.

Independently tested via HPLC and LC-MS. COA downloadable on this page.

They regulate appetite through different brain circuits. Amylin acts primarily through the brainstem (area postrema). GLP-1 acts through both brainstem and hypothalamic circuits. Combination research investigates whether targeting both produces effects beyond either alone.

Every Batch Tested by an Independent Lab

We publish the Certificate of Analysis for every product. See our full testing process.

See Our Standards →

All products sold by OSYRIS Health are intended for laboratory research purposes only and are not for human or veterinary use. The information provided on this page describes published scientific research and does not constitute medical advice, diagnosis guidance, or a recommendation for any specific use. Always ensure compliance with local regulations.